Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis. Survival is comparably poor for patients who develop metastases directly after non-muscle invasive ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...

Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of ...

Analysis of the results of intravesical perfusion therapy combined with immediate or non-immediate hematoporphyrin intravesical perfusion photodynamic therapy (PDT) after TURBT for NMIBC. This is an ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...

Bladder cancer is mainly urothelial carcinoma, with non-muscle-invasive and muscle-invasive types, and smoking as a key risk factor. Diagnosis involves cystoscopy, biopsy, urine cytology, and imaging ...

ImmunityBio (NasdaqGS:IBRX) has had its resubmitted supplemental Biologics License Application for ANKTIVA plus BCG in papillary non muscle invasive bladder cancer formally acknowledged by the FDA.

Bladder cancer imaging and diagnosis have evolved significantly with the integration of advanced magnetic resonance imaging (MRI) techniques and artificial intelligence (AI)-driven analytical methods.